DK1248849T3 - Globulært OBG3-hoved og anvendelser deraf til reduktion af kropsmasse - Google Patents

Globulært OBG3-hoved og anvendelser deraf til reduktion af kropsmasse

Info

Publication number
DK1248849T3
DK1248849T3 DK01942383T DK01942383T DK1248849T3 DK 1248849 T3 DK1248849 T3 DK 1248849T3 DK 01942383 T DK01942383 T DK 01942383T DK 01942383 T DK01942383 T DK 01942383T DK 1248849 T3 DK1248849 T3 DK 1248849T3
Authority
DK
Denmark
Prior art keywords
body mass
obg3
obesity
global
applications
Prior art date
Application number
DK01942383T
Other languages
Danish (da)
English (en)
Inventor
Bernard Bihain
Mary Ruth Erickson
Frances Yen-Potin
Joachim Fruebis
Original Assignee
Serono Genetics Inst Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Inst Sa filed Critical Serono Genetics Inst Sa
Application granted granted Critical
Publication of DK1248849T3 publication Critical patent/DK1248849T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
DK01942383T 2000-01-14 2001-01-10 Globulært OBG3-hoved og anvendelser deraf til reduktion af kropsmasse DK1248849T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17622800P 2000-01-14 2000-01-14
US19808700P 2000-04-13 2000-04-13
US22988100P 2000-09-01 2000-09-01
PCT/IB2001/000084 WO2001051645A1 (en) 2000-01-14 2001-01-10 Obg3 globular head and uses thereof for decreasing body mass

Publications (1)

Publication Number Publication Date
DK1248849T3 true DK1248849T3 (da) 2008-12-08

Family

ID=27390648

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01942383T DK1248849T3 (da) 2000-01-14 2001-01-10 Globulært OBG3-hoved og anvendelser deraf til reduktion af kropsmasse

Country Status (14)

Country Link
EP (1) EP1248849B1 (es)
JP (1) JP4698914B2 (es)
AT (1) ATE405655T1 (es)
AU (1) AU785090B2 (es)
BR (1) BR0107626A (es)
CA (1) CA2383136C (es)
CY (1) CY1108461T1 (es)
DE (1) DE60135439D1 (es)
DK (1) DK1248849T3 (es)
ES (1) ES2312450T3 (es)
IL (2) IL150554A0 (es)
MX (1) MXPA02006834A (es)
PT (1) PT1248849E (es)
WO (1) WO2001051645A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153200A0 (en) 2000-05-31 2003-07-06 Genset Sa PHARMACEUTICAL COMPOSITIONS COMPRISING A gOBG3
WO2003009862A1 (en) * 2001-07-20 2003-02-06 Genset S.A. Agonists and antagonists of modumet for use in the treatment of metabolic disorders
WO2003009864A1 (en) * 2001-07-23 2003-02-06 Genset S.A. Agonists and antagonists of disomet for the treatment of metabolic disorders
WO2003009861A1 (en) * 2001-07-24 2003-02-06 Genset S.A. Agonists and antagonists of metabolix in the treatment of metabolic disorders
WO2003009865A1 (en) * 2001-07-25 2003-02-06 Genset S.A. Agonists and antagonists of energen for use in the treatment of metabolic disorders
WO2003009863A1 (en) * 2001-07-26 2003-02-06 Genset S.A. Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
WO2003011325A1 (en) * 2001-07-27 2003-02-13 Genset S.A. Agonists and antagonists of moceptin for the treatment of metabolic disorders
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
WO2003011321A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of cobesin for the treatment of metabolic disorders
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
WO2003011318A1 (en) * 2001-08-01 2003-02-13 Genset S.A. Agonists and antagonists of famoset for use in the treatment of metabolic disorders
WO2003022299A1 (en) * 2001-08-01 2003-03-20 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
WO2003011320A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of obesingen for the treatment of metabolic disorders
WO2003011319A1 (en) * 2001-08-02 2003-02-13 Genset S.A Xobesin agonists and antagonists for the treatment of metabolic disorders
WO2003011322A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
WO2003013579A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Lypergix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013580A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Tr xidatin agonists and antagonists treatment of metabolic disorders
WO2003013581A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Agonists and antagonists of genceptin for the treatment of metabolic disorders
WO2003013582A1 (en) * 2001-08-06 2003-02-20 Genset S.A. Genoxit agonists and antagonists for use in the treatment of metabolic disorders
WO2003013578A1 (en) * 2001-08-07 2003-02-20 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
WO2003013585A1 (en) * 2001-08-08 2003-02-20 Genset S.A. Mifaxin agonists and antagonists for use in the treatment of metabolic
AU2002339213A1 (en) * 2001-08-09 2003-02-24 Genset S.A. Migenix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013583A1 (en) * 2001-08-10 2003-02-20 Genset S.A. Faxigen agonists and antagonists in the treatment of metabolic disorders
WO2003026695A1 (en) * 2001-09-21 2003-04-03 Genset S.A. Agonists and antagonists of cylixin for the treatment of metabolic disorders
ES2295415T3 (es) 2001-10-05 2008-04-16 Serono Genetics Institute S.A. Fragmentos de la glicoproteina zn-alfa2 humana y su uso en metodos de tratamiento de la obesidad.
WO2003041730A1 (en) * 2001-11-16 2003-05-22 Genset S.A. Ditacin agonists and antagonists for use in the treatment of metabolic disorders
US20060089311A1 (en) * 2001-11-28 2006-04-27 Deno Dialvnas Agonists and antagonists of ryzn for the treatment of metabolic disorders
US7344843B2 (en) 2001-11-29 2008-03-18 Serono Genetics Institute S.A. Agonists and antagonists of prolixin for the treatment of metabolic disorders
AU2002339689A1 (en) * 2001-12-05 2003-06-17 Genset S.A. Dexar agonists and antagonists for use in the treatment of metabolic disorders
WO2003047614A1 (en) * 2001-12-05 2003-06-12 Genset S.A. Agonist and antagonists of redax for the treatment of metabolic disorders
WO2003049757A1 (en) * 2001-12-12 2003-06-19 Genset S.A. Agonists and antagonists of glucomin for the treatment of metabolic disorders
AU2002339685A1 (en) * 2001-12-13 2003-06-23 Genset S.A. Agonists and antagonists of oxifan for the treatment of metabolic disorders
WO2003049756A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Glucomin agonists and antagonists for use in the treatment of metabolic disorders
WO2003049758A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Emergen agonists and antagonists for use in the treatment of metabolic disorders
AU2002339688A1 (en) * 2001-12-14 2003-06-30 Genset S.A. Glucoset agonists and antagonists for use in the treatment of metabolic disorders
JP2005526492A (ja) * 2001-12-21 2005-09-08 マキシゲン・エイピーエス アディポネクチンフラグメントおよび結合体
WO2003055509A1 (en) * 2001-12-26 2003-07-10 Genset S.A. Agonists and antagonists of bromix for the treatment of metabolic disorders
US20050288223A1 (en) * 2002-05-17 2005-12-29 Genset S.A. OBG3 Fragments Inhibiting The Conversion Of Active OBG3 Into Less Active OBG3 And Other Compositions For Treatment Of Metabolic Disorders
US7459433B2 (en) 2002-05-31 2008-12-02 Serono Genetics Institute, S.A. Homotrimeric extended OBG3 globular head and uses thereof
EP1641444B1 (en) * 2003-06-02 2016-03-23 Isis Innovation Limited Treatment of muscle fatigue
AU2004245567B2 (en) 2003-06-03 2011-06-23 Oxford University Innovation Limited Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives
CA2542142A1 (en) * 2003-10-09 2005-05-19 Trustees Of Boston University Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis
EP1744160B1 (en) 2004-03-31 2011-07-06 Kazuhisa Maeda Use of adiponectin as marker in the prediction of post-operative infection
CN1740195B (zh) * 2005-04-15 2012-01-04 复旦大学 一种多肽gapM1及其制备方法
EP2041166A1 (en) * 2006-06-20 2009-04-01 Laboratoires Serono SA Process for globular adiponectin production
EP2240017B1 (en) 2008-01-04 2019-03-13 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
EP2088156A1 (en) 2008-02-08 2009-08-12 Institut Pasteur Use of adiponectin for the diagnosis and/or treatment of presbycusis
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
AU2013337308B2 (en) 2012-11-05 2018-06-21 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869330A (en) * 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
WO1999021577A1 (fr) * 1997-10-29 1999-05-06 Otsuka Pharmaceutical Co., Ltd. Compositions inhibant la proliferation des muscles lisses, procede de diagnostic de l'arteriosclerose et trousses correspondantes

Also Published As

Publication number Publication date
JP4698914B2 (ja) 2011-06-08
MXPA02006834A (es) 2005-07-01
IL150554A (en) 2009-05-04
BR0107626A (pt) 2002-10-15
ES2312450T3 (es) 2009-03-01
AU785090B2 (en) 2006-09-14
WO2001051645A1 (en) 2001-07-19
EP1248849B1 (en) 2008-08-20
AU5789901A (en) 2001-07-24
EP1248849A1 (en) 2002-10-16
IL150554A0 (en) 2003-02-12
DE60135439D1 (de) 2008-10-02
CY1108461T1 (el) 2014-04-09
ATE405655T1 (de) 2008-09-15
JP2003519633A (ja) 2003-06-24
PT1248849E (pt) 2008-09-08
CA2383136C (en) 2012-09-18
CA2383136A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
DK1248849T3 (da) Globulært OBG3-hoved og anvendelser deraf til reduktion af kropsmasse
EA200300944A1 (ru) Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
DE60205465D1 (de) Piperazinderivate als agonisten des melanocortin-rezeptors
ATE411021T1 (de) Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten
NO20043632L (no) 2,4-pyrimidinaminforbindelser og deres anvendelser
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
HRP20041180A2 (en) 11-beta-hidroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
ATE341327T1 (de) Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
DE60232238D1 (de) Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten
NO20034996D0 (no) Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser
WO2003106629A3 (en) TREATMENT OF VITAMIN D INFLUENCED DISEASES
NO20043441L (no) Orodispersibel farmasoytisk sammensetning omfattende agomelatin
WO2003010197A3 (en) Gmg-1 polynucleotides and polypeptides and uses thereof
DE60331769D1 (de) Sten in der behandlung von u.a. sexueller dysfunktion
DK1432803T3 (da) Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas
WO2003009871A3 (en) Inhibitors of plasminogen activator inhibitor for decreasing body mass
BR0108749A (pt) Antagonistas de receptor il-8
ATE416783T1 (de) Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности
EP1509545B8 (en) Homotrimeric extended obg3 globular head and uses thereof
DE60128374D1 (de) Varianten des hauptallergen par j 2 von parietaria judaica
WO2002044374A3 (en) Flea gaba receptor subunit nucleic acid molecules, proteins and uses thereof
WO2003082915A3 (en) Xcrf polynucleotides and polypeptides and uses thereof